Technology area: Biotechnology & Pharmaceuticals
39 pending office actions • 7 art units • 24 examiners • 0 of 39 (0%) have an AI response strategy ready • 28 patents granted in the last 365 days
Alnylam Pharmaceuticals Inc. has 41 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 25 examiners and 7 art units, combining substantial pending volume with broad examiner coverage and concentration within a smaller set of technical groups.
HUDSON, AMY ROSE is the busiest examiner, with 6 pending matters. That assignment represents the most visible examiner concentration in the profile, although the remaining matters require coordination across many other examiner relationships.
The 7 art units provide a useful structure for portfolio oversight. Counsel can organize reviews by technical group, track recurring claim and prior-art issues, and preserve application-specific positions where examiner treatment differs.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 7 (18%) |
| §103 only | 8 (21%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 10 (26%) |
| Multi-statute (no §101) | 11 (28%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 5 | 74.8% | +11.7% |
| TRAN, CHRISTINA L | 4 | 51.6% | +49.8% |
| GIBBS, TERRA C | 3 | 63.7% | +10.4% |
| VYAS, KEYUR ANILKUMAR | 3 | 50.0% | +58.7% |
| ZAHORIK, AMANDA MARY | 2 | 58.3% | +49.3% |
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| YU, DELPHINUS DOU YI | 2 | 33.3% | +0.0% |
| POLIAKOVA-GEORGAN, EKATERINA | 2 | 63.9% | +18.1% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 9d overdue |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 30d |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 69d |
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | ZAHORIK, AMANDA MARY | — |
| 18623281 | RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP) | BRETZ, COREY LANE | — |
| 18423377 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | GROOMS, TIFFANY NICOLE | — |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | LEE, HOI YAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 110d overdue |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 52d overdue |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 38d overdue |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 9d overdue |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 4d overdue |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 79d |
| Art Unit | Apps |
|---|---|
| 1637 | 15 |
| 1636 | 12 |
| 1635 | 6 |
| 1693 | 3 |
| 1628 | 1 |
| 1691 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | ZAHORIK, AMANDA MARY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 1635 | §101§102§103§112 | Final Rejection | 9d overdue | Pending | Apr 16, 2024 |
| 18623281 | RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP) | BRETZ, COREY LANE | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | CHO, DAVID H | 1693 | §102§103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §103Other | Non-Final OA | 79d | Pending | Feb 20, 2024 |
| 18423377 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | GROOMS, TIFFANY NICOLE | 1637 | §101§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | LEE, HOI YAN NMN | 1693 | §102§103§112Other | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18577377 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | ZAHORIK, AMANDA MARY | 1636 | §103 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18405072 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §103§112Other | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18403862 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING OR AT RISK OF DEVELOPING A NON-PRIMARY HYPEROXALURIA DISEASE OR DISORDER | WHITEMAN, BRIAN A | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18542950 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | GIBBS, TERRA C | 1635 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18541755 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18525922 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | YU, DELPHINUS DOU YI | 1636 | §101§102§103 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18389245 | SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ZARA, JANE J | 1637 | §101§103 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112DP | Non-Final OA | 38d overdue | Pending | Oct 03, 2023 |
| 18373397 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18551668 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SU-TOBON, QIWEN NMN | 1636 | §101§103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18243133 | GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §101§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18548634 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18236437 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | YU, DELPHINUS DOU YI | 1636 | §103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18547102 | FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF | KONOPKA, CATHERINE ANNE | 1636 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 1635 | §103§112 | Final Rejection | 69d | Pending | Jun 29, 2023 |
| 18215849 | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GIBBS, TERRA C | 1635 | §101 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18206116 | COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112 | Final Rejection | — | Pending | Jun 06, 2023 |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 1637 | §102§103DP | Final Rejection | 52d overdue | Pending | May 26, 2023 |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112DP | Final Rejection | 14d | Pending | Apr 19, 2023 |
| 18136386 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18131892 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | ANGELL, JON E | 1637 | §102§103 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103§112 | Final Rejection | 85d overdue | Pending | Feb 09, 2023 |
| 18015202 | Circular siRNAs | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Jan 09, 2023 |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 4d overdue | Pending | Oct 27, 2022 |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Oct 05, 2022 |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 1637 | §103§112 | Non-Final OA | 30d | Pending | Aug 24, 2022 |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 26d overdue | Pending | May 25, 2022 |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112DP | Final Rejection | 110d overdue | Pending | Mar 01, 2022 |
| 17668413 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112 | Final Rejection | — | Pending | Feb 10, 2022 |
| 17619633 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | MCKILLOP, JOHN CHARLES | 1637 | §112DP | Final Rejection | — | Pending | Dec 16, 2021 |
| 17392122 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | VIVLEMORE, TRACY ANN | 1638 | §102§103 | Non-Final OA | — | Pending | Aug 02, 2021 |
| 17250952 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103 | Non-Final OA | 230d overdue | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlnylam Pharmaceuticals Inc. has 39 pending office actions as of October 2026, spread across 7 art units and 24 examiners.
Amy Rose Hudson has the most, with 5 of Alnylam Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
